Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT02042807
PHASE2
To Evaluate the Effect of MCS® in Prostate Cancer Prevention
Sponsor: Health Ever Bio-Tech Co., Ltd.
View on ClinicalTrials.gov
Summary
To evaluate the effect of MCS® compared with placebo in reducing the risk of biopsy-detectable prostate cancer in high-risk subjects after 104 weeks (24 months) of treatment.
Official title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS® in Prostate Cancer Prevention
Key Details
Gender
MALE
Age Range
50 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
702
Start Date
2014-10
Completion Date
2024-12
Last Updated
2024-06-13
Healthy Volunteers
No
Conditions
Interventions
DRUG
Placebo
DRUG
MCS®
Locations (1)
Department of Urology, National Taiwan University Hospital
Taipei, Taiwan